Citations

Citations to this article as recorded by  

• Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Added to Dual or Triple Treatment in Patients with Type 2 Diabetes Mellitus
  Yesol Hong, Yoomin Jeon, Yoona Choi, Tae Kyu Chung, Howard Lee
  Diabetes Therapy.2024; 15(2): 487.     CrossRef
• Real-world assessment of effectiveness and safety profile of remogliflozin etabonate in management of type 2 diabetes mellitus
  Bipin Sethi, Subhankar Chowdhury, Supratik Bhattacharya, Sagar Katare, Sachin Suryawanshi, Hanmant Barkate
  International Journal of Diabetes in Developing Countries.2023; 43(2): 214.     CrossRef
• Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study
  Hyeong Kyu Park, Kyoung‐Ah Kim, Kyung‐Wan Min, Tae‐Seo Sohn, In Kyung Jeong, Chul Woo Ahn, Nan‐Hee Kim, Ie Byung Park, Ho Chan Cho, Choon Hee Chung, Sung Hee Choi, Kang Seo Park, Seoung‐Oh Yang, Kwan Woo Lee
  Diabetes, Obesity and Metabolism.2023; 25(9): 2743.     CrossRef
• Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
  Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
  Diabetes & Metabolism Journal.2023; 47(6): 808.     CrossRef
• Real-world Data of Glycemic Control in a Suburban Population in Northern India during the COVID-19 Pandemic
  Jaydip V. Revale, Preeti J. Revale
  International Journal of Diabetes and Technology.2023; 2(2): 60.     CrossRef
• Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
  Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas
  Irish Journal of Medical Science (1971 -).2022; 191(4): 1647.     CrossRef
• Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
  Nauman Wazir, Shafqat Ur Rehman
  Journal of Gandhara Medical and Dental Science.2022; 9(1): 24.     CrossRef
• Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus
  Wajd Alkabbani, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, Dean T. Eurich, Baiju R. Shah, Mhd. Wasem Alsabbagh, John‐Michael Gamble
  Diabetic Medicine.2022;[Epub]     CrossRef
• Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
  Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
  Yonsei Medical Journal.2022; 63(9): 825.     CrossRef
• Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
  Ha Young Jang, In-Wha Kim, Jung Mi Oh
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
  Ai-Yu Yang, Hung-Chun Chen
  International Journal of Clinical Pharmacy.2021; 43(4): 1015.     CrossRef
• Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
  Zhiqin Zhang, Lihua Ni, Lian Zhang, Dongqing Zha, Chun Hu, Lingli Zhang, Huiling Feng, Xiaobao Wei, Xiaoyan Wu
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 227.     CrossRef
• Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
  Hiroaki Seino
  Diabetes Therapy.2021; 12(3): 863.     CrossRef
• Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study
  Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon, Young-Jung Roh
  Diabetes Care.2021; 44(10): 2419.     CrossRef
• Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
  Muhammad Afzal, Fahad Al-Abbasi, Muhammad Nadeem, Sultan Alshehri, Mohammed Ghoneim, Syed Imam, Waleed Almalki, Imran Kazmi
  Metabolites.2021; 11(11): 794.     CrossRef
• Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
  Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
  Diabetes & Metabolism Journal.2020; 44(4): 489.     CrossRef
• Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
  Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
  Kidney Research and Clinical Practice.2020; 39(3): 269.     CrossRef
• Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
  Jung-Fu Chen, Yun-Shing Peng, Chung-Sen Chen, Chin-Hsiao Tseng, Pei-Chi Chen, Ting-I Lee, Yung-Chuan Lu, Yi-Sun Yang, Ching-Ling Lin, Yi-Jen Hung, Szu-Ta Chen, Chieh-Hsiang Lu, Chwen-Yi Yang, Ching-Chu Chen, Chun-Chuan Lee, Pi-Jung Hsiao, Ju-Ying Jiang, S
  PeerJ.2020; 8: e9998.     CrossRef
• Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
  Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti
  Journal of Diabetes Research.2019; 2019: 1.     CrossRef
• An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
  Ji A Seo
  Diabetes & Metabolism Journal.2019; 43(5): 578.     CrossRef